Abello Pharmaceuticals was founded in 1925 by pharmacist Juan Abello Pascual and specialized in manufacturing oxygen- and alkaline-based therapeutics as well as synthetic hormones, among other processes and products. 2000: Acquires Center Laboratories, one of the leading suppliers of allergenic extracts in the U.S.  2006: The world’s first registered sublingual immunotherapy tablet (SLIT-tablet), for grass pollen allergy, is launched 2007: An agreement is signed with Schering-Plough (which merged with Merck & Co. in November 2009) to develop, register and commercialize in North America a portfolio of SLIT-tablet treatments for grass, ragweed and house dust mite allergy 2009: The Grazax Asthma Prevention (GAP) trial, investigating the potential for preventing the development of asthma in children and adolescents is initiated.  2011: A new ALK-developed adrenaline auto-injector for the treatment of acute anaphylaxis is launched 2011: An agreement with Torii Pharmaceutical Co., Ltd. to develop, register and commercialize a number of SLIT-tablet products in Japan is signed. The agreement also covers selected existing ALK products and diagnostics against house dust mite allergy. It also covers a research and development contract to develop a sublingual immunotherapy tablet against Japanese cedar pollen allergy. 2014: The grass and ragweed SLIT-tablets are launched in the US. 2014: ALK signs collaboration agreements with Eddingpharm for China and Abbott for Russia and selected emerging markets. 2015: ALK signs a collaboration agreement with bioCSL (now Seqirus) covering Australia and New Zealand. 2016: ALK expands its partnership with Abbott to cover seven markets in South-East Asia and terminates its partnerships with Merck and EddingPharm. 2016: The house dust mite SLIT-tablet is launched in Europe and Japan. Since launching the first SLIT-tablet (for grass allergy) in 2006, ALK has been developing tablets for other allergies, including tree, ragweed and house dust mite. Its strategy is to develop more patient-friendly treatments based on the approach of 're-educating' the immune system.